Clinical Trial Update: Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the combination of alisertib with abiraterone acetate and prednisone in hormone-resistant prostate cancer has completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Alisertib (alisertib)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-12-06